Nucana receives fast track designation from the u.s. food and drug administration for acelarin® (nuc-1031) for the treatment of biliary tract cancer

Edinburgh, united kingdom, sept. 29, 2021 (globe newswire) -- nucana plc (nasdaq: ncna) announced that the u.s. food and drug administration (fda) has granted fast track designation to acelarin (nuc-1031), currently being evaluated in a phase iii study (nutide:121) for the first-line treatment of patients with advanced biliary tract cancer. fast track is a process designed to facilitate the development and expedite the review of drugs to treat serious conditions and address an unmet medical need.
NCNA Ratings Summary
NCNA Quant Ranking